orfiril magasýruþolin tafla 150 mg
desitin arzneimittel gmbh - natrii valproas - magasýruþolin tafla - 150 mg
orfiril magasýruþolin tafla 600 mg
desitin arzneimittel gmbh - natrii valproas - magasýruþolin tafla - 600 mg
orfiril mixtúra, lausn 60 mg/ml
desitin arzneimittel gmbh - natrii valproas - mixtúra, lausn - 60 mg/ml
lumoxiti
astrazeneca ab - moxetumomab pasudotox - hvítblæði, hairy cell - Æxlishemjandi lyf - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
marixino (previously maruxa)
krka, d.d. - memantínhýdróklóríð - alzheimer sjúkdómur - Önnur lyf gegn vitglöpum - meðferð sjúklinga með miðlungsmikla til alvarlega alzheimerssjúkdóma.
axura
merz pharmaceuticals gmbh - memantínhýdróklóríð - alzheimer sjúkdómur - Önnur lyf gegn vitglöpum - meðferð sjúklinga með miðlungsmikla til alvarlega alzheimerssjúkdóma.
ebixa
h. lundbeck a/s - memantínhýdróklóríð - alzheimer sjúkdómur - Önnur lyf gegn vitglöpum - meðferð sjúklinga með miðlungsmikla til alvarlega alzheimerssjúkdóma.
nemdatine
actavis group ptc ehf. - memantín - alzheimer sjúkdómur - psychoanaleptics, , Önnur anti-heilabilun lyf - meðferð sjúklinga með miðlungsmikla til alvarlega alzheimerssjúkdóma.
tecvayli
janssen-cilag international n.v. - teclistamab - mergæxli - Æxlishemjandi lyf - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
lunsumio
roche registration gmbh - mosunetuzumab - eitilæxli, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.